Isofol Medical (Sweden) Today
| ISOFOL Stock | SEK 2.99 0.11 3.82% |
Performance3 of 100
| Odds Of DistressOver 64
|
Isofol Medical is trading at 2.99 as of the 1st of December 2024, a 3.82 percent increase since the beginning of the trading day. The stock's open price was 2.88. Isofol Medical has more than 64 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Isofol Medical AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of September 2024 and ending today, the 1st of December 2024. Click here to learn more.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 161.52 M outstanding shares. More on Isofol Medical AB
Moving against Isofol Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Isofol Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Isofol Medical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Isofol Medical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jarl Jungnelius |
| Thematic Idea | Drugs (View all Themes) |
| Business Concentration | Drugs, Biotechnology, Healthcare (View all Sectors) |
Isofol Medical AB (ISOFOL) is traded on Stockholm Exchange in Sweden and employs 15 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 109.18 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Isofol Medical's market, we take the total number of its shares issued and multiply it by Isofol Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Isofol Medical AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 161.52 M outstanding shares.
Isofol Medical AB has accumulated about 379.45 M in cash with (188.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93.
Check Isofol Medical Probability Of Bankruptcy
Ownership AllocationIsofol Medical AB has a total of 161.52 Million outstanding shares. Isofol Medical secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Isofol Ownership Details
Isofol Medical AB Risk Profiles
Although Isofol Medical's alpha and beta are two of the key measurements used to evaluate Isofol Medical's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.95 | |||
| Semi Deviation | 4.47 | |||
| Standard Deviation | 6.03 | |||
| Variance | 36.32 |
Isofol Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Isofol Medical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Isofol Medical Corporate Directors
| Magnus Bjorsne | Director | Profile | |
| Karin Ganlov | Senior Medical Director | Profile | |
| Paula Boultbee | Director | Profile | |
| Anna Belfrage | Director | Profile |
Other Information on Investing in Isofol Stock
Isofol Medical financial ratios help investors to determine whether Isofol Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isofol with respect to the benefits of owning Isofol Medical security.